Why Dementia is Associated with Poor Morbidity and Novel Treatments: An In-Depth Discussion about Alzheimer’s Disease

Abstract

One of the most common forms of dementia around the world is Alzheimer’s. By 2022, it is estimated one out of every three seniors diagnosed with Alzheimer’s will eventually die due to complications from the disease [1]. There are several biological and physical markers of Alzheimer’s that may indicate that one has the disease, with symptoms all relating to a decline in cognitive function. The general development of Alzheimer’s is ascribed to two factors, genetic and environmental. Along with the growth of an aging population and the absence of a definitive cure, the search for novel treatments has gained significant momentum. Some promising treatments include: immunotherapies targeting amyloid-beta plaques, such as the monoclonal antibody ‘donanemab’; precision medicine for personalized therapies, namely deep brain stimulation (DBS); and TRIM11 as a biological target for the slowing of the decline in cognitive abilities. Despite progression in the development of novel treatments, the pathophysiological mechanism of the disease is yet to be understood, accounting for various trial-and-error type experiments. Continued research and a comprehensive approach are vital for the development of effective therapies for Alzheimer’s disease.